<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: <z:chebi fb="0" ids="31348">Capecitabine</z:chebi> plus <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (XELOX) is an effective second-line regimen for advanced colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients pretreated with irinotecan </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies have shown supra-additive anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activity of <z:chebi fb="0" ids="175901">gemcitabine</z:chebi> (GEM) when administered with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated the dose, toxicity, and efficacy of a second-line XELOXGEM regimen in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients pretreated with irinotecan </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Patients with metastatic or recurrent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> who failed after a first-line irinotecan-containing regimen received escalating doses of <z:chebi fb="0" ids="175901">gemcitabine</z:chebi> (600, 800, 1,000 mg/m(2) d1, d8) followed by <z:chebi fb="0" ids="31348">capecitabine</z:chebi> (1,000 mg/m(2) b.i.d d1-14) and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (100 mg/m(2) d1) on a 21-day cycle </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: A total of 38 patients were treated </plain></SENT>
<SENT sid="5" pm="."><plain>At 800 mg/m(2), two of six patients experienced dose-limiting toxicities (<z:hpo ids='HP_0002014'>diarrhea</z:hpo> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>) </plain></SENT>
<SENT sid="6" pm="."><plain>Therefore, the clinically recommended dose was defined as 600 mg/m(2) <z:chebi fb="0" ids="175901">gemcitabine</z:chebi> (d1, d8) followed by 1,000 mg/m(2) <z:chebi fb="0" ids="31348">capecitabine</z:chebi> (b.i.d dl-14) and 100 mg/m(2) <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (d1) </plain></SENT>
<SENT sid="7" pm="."><plain>The most common grade 3/4 toxicities were <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (32%), <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (13%), <z:hpo ids='HP_0001903'>anemia</z:hpo> (11%), and <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> (11%) </plain></SENT>
<SENT sid="8" pm="."><plain>Ten (26.3%) and 23 (60.5%) patients experienced partial response and stable disease, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>The median progression-free survival and overall survival were 5.4 months (95% CI 3.8-6.9 months) and 17.7 months (95% CI 8.4-26.9 months), respectively </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The XELOXGEM triplet combination is an active and safe second-line regimen for advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients pretreated with irinotecan </plain></SENT>
</text></document>